Citations

Clear

13603 citation(s) found for "_, _".

Preserved transcriptional networks in immune signaling pathways associated with chronic disease identified in Alzheimer’s disease and Parkinson’s disease, cross‐tissue analysis
Strickland, Samantha L. , Tsai, Wei, Chen, Xuan , Cherukuri, Yesesri , Allen, Mariet , Quicksall, Zachary , Wang, Xue , Carrasquillo, Minerva M. , Nho, Kwangsik, Petersen, Ronald C., Reddy, Joseph S. , Ertekin‐Taner, Nilüfer , Kantarci, Kejal , Carrasquillo, Minerva M. , Saykin, Andrew J. , Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.092349 Get It

AbstractBackgroundSystemic inflammation plays a pivotal role in many chronic diseases including Alzheimer’s disease (AD). Assessing the composition of immune pathways in neurodegenerative diseases can contribute to precision medicine. Using publicly available transcriptomic data, we sought to elucidate transcriptional networks pertinent to inflammatory pathways across brain regions and peripheral blood in AD/mild cognitive impairment (MCI) and peripheral blood in Parkinson’s disease (PD).MethodFor the AD/MCI vs. control dataset, we analyzed bulk‐RNAseq collected from 6 brain regions of donors from ROSMAP, Mayo Clinic, and Mount Sinai School of Medicine (MSSM) brain banks available from the AMP‐AD consortium. Ante‐mortem, blood RNAseq expression data was retrieved from the AMP‐AD Emory Vascular cohort and Mayo Clinic Study of Aging (MCSA). We also collected blood‐derived microarray expression data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). For the PD vs Control dataset, blood‐derived bulk‐RNAseq from the PDBP and PPMI cohorts were available through the AMP‐PD consortium. Following quality control, normalization, and residual generation to account for biological and technical variables, co‐expression network modules and their enriched pathways were identified using WGCNA within each dataset. Module/trait correlation tests for aging and diagnosis (cases [AD/MCI or PD] vs control) phenotypes were evaluated. Gene Ontology enrichment analyses were executed to identify enriched pathways and brain or blood cell types within the modules. Modules were tested for preservation across cohorts.ResultWe identified conserved immune signatures across brain regions and cohorts. Modules involved in immune response were preserved across all cohorts. Blood consensus modules involved in immune response were preserved in the brain and vice versa. Some immune modules were associated with AD/MCI, PD, and/or aging. Brain immune modules are significantly associated with aging and/or AD. Significant correlations (q<0.05) with PD diagnosis were present. In the MCSA and Emory vascular cohorts, there were no significant (q<0.05) associations between modules and diagnosis, while in ADNI there were nominal (p<0.05) associations.ConclusionPreserved transcriptional immune networks were identified across blood and brain and across two neurodegenerative diseases. Expanding gene co‐expression network analyses to other diseases and integrating additional omics measures and phenotypes can further strengthen these findings to unravel the immune signatures across complex diseases.
P2RX7 deficiency prevents cognitive deficit, brain atrophy and tauopathy progression in PS19 mice via suppression of extracellular vesicle secretion and mitochondrial toxicity
Santos, Victor B, Ellison, Justice, Ikezu, Seiko , Abdullah, Mohammad, Ellison, Justice, Ruan, Zhi , Ikezu, Tsuneya

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.088010 Get It

AbstractBackgroundWe previously identified the novel mechanism of pathological tau transfer via extracellular vesicles (EVs) in Alzheimer’s disease (AD). Targeting EV secretion to mitigate tau transfer is therefore a promising therapeutic approach for AD. P2X purinoreceptor 7 (P2RX7), an ATP‐gated cationic channel, regulates microvesicle shedding or secretion of multivesicular body‐derived exosomes. We aim to investigate the effect of P2rx7 deficiency on disease progression in PS19 tauopathy mouse model in vivo and by proteomic profiling of brain EVs.MethodPS19:P2rx7–/– mice at 9 months of age were tested for the fear conditioning, and pathology assessment of the brain atrophy and tau using immunofluorescence against aggregated tau (Alz50) or phosphorylated tau (AT8) and ELISA. Mice were intracranially injected with viral vectors expressing mEmerald‐CD9 in microglia and P301L tau in neurons to visualize the secretion of microglial EV and extracellular tau in vivo. Brain EV samples were subjected to proteomic profiling by data independent acquisition mass‐spectrometry.ResultPS19:P2rx7–/– mice showed significant improvement in contextual and cued memory compared to age‐matched PS19 mice, which was accompanied by preserved cortical and hippocampal volume, and significant reduction of hippocampal tau pathology and pS396 tau in sarkosyl‐insoluble fraction of brain tissues. The number of GFP+ microglial EVs were significantly reduced in P2rx7–/– compared to WT mice. Gene ontology pathway analysis of EV proteome showed significant enrichment of mitochondrial pathways in PS19 group compared to WT group, which was significantly downregulated in PS19:P2rx7–/– group.ConclusionOur study demonstrated that P2rx7 deficiency ameliorates cognitive dysfunction and tau pathology development in PS19 mice by dampening microglial EV secretion and EV‐mediated mitochondria transfer, further indicating the therapeutic potential of targeting P2RX7, an EV regulatory molecule, to ameliorate AD progression.
Tangle distribution is differentially influenced by age at onset, APOE ε4, and MAPT H1 along the corticolimbic axis
Boon, Baayla D.C.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.083978 Get It

AbstractBackgroundAlzheimer’s disease (AD) is heterogeneous in both its clinical and neuropathologic course. Age at onset and distribution of corticolimbic tangles can vary widely among individuals. Genetic risk factors APOE ε4 and MAPT H1 increase AD risk. However, the association with the spatial distribution of pathology remains a key gap in knowledge. We investigated the effects of age at onset, APOE ε4, MAPT H1, and family history of cognitive symptoms on corticolimbic tangle density variability to better distinguish how each factor contributes.MethodThe FLorida Autopsied Multi‐Ethnic (FLAME) cohort was queried for neuropathologically confirmed AD cases (n = 1233). Tangle density (count per 0.125mm2) was quantified using thioflavin‐S staining in nucleus basalis of Meynert (nbM), hippocampal CA1 and subiculum, association cortices, and primary cortices. Cortical thickness was measured using digital pathology on hematoxylin‐eosin‐stained sections. We employed univariate and multivariate negative binomial regression models to evaluate the association of each factor on tangle density across the corticolimbic axis. Multivariate analysis was adjusted for significant variables from univariate analyses.ResultDonors with young‐onset (<65) AD (YOAD; n = 314) had more tangles than those with late‐onset AD (LOAD; n = 919) across most corticolimbic regions (Fig. 1). Except for CA1, younger age at onset was associated with a higher expected tangle density with an increase ranging from 8% in subiculum up to 99% in motor cortex (Table 1). Male sex was associated with lower expected tangle density throughout all corticolimbic regions. Being male associated the strongest in visual cortex with a 41% tangle density decrease. The APOE ε4 allele associated with an increase of tangle density in the nbM, CA1, subiculum, and visual cortex, whereas the MAPT H1 haplotype associated with a decrease in association and motor cortices. A positive family history for cognitive problems was associated with a 16% decrease of tangle density in visual cortex. Tangle density correlated closely with (sub)cortical thickness in the CA1+subiculum, superior temporal, inferior parietal, and middle frontal cortex (Spearman Rho = ‐0.39 ‐ ‐0.58, p<0.001).ConclusionThese data contribute to the concept that brain regions may experience aging and genetics differentially, underlining the need to distinguish these aspects when investigating AD disease mechanisms.
Accuracy of intact performance on measures of odor identification, global cognition, and amyloid imaging for identifying lack of cognitive decline and dementia in the Mayo Clinic Study of Aging cohort
Motter, Jeffrey N. , Lee, Seonjoo, Vassilaki, Maria , Devanand, Davangere P. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.088601 Get It

AbstractBackgroundPrevious studies have linked impaired odor identification and global cognition with increased risk of cognitive decline and transition to dementia. However, the reverse question remains: if individuals have intact performance on these measures, are they at reduced risk for transition? We aimed to examine the accuracy of intact odor identification and global cognition for identifying lack of transition to dementia/cognitive decline using the population‐based Mayo Clinic Study of Aging and compare their accuracy against and in combination with amyloid PET (Positron Emission Tomography).Methodn = 647 participants age≥55 without dementia completed at baseline the Brief Smell Identification Test (BSIT; ‘Intact’ = 9‐12), Blessed Information‐Memory‐Concentration Test (BIMCT; ‘Intact’ = 18‐20,), and amyloid PET (‘Normal/Intact’ SUVR<1.48). We calculated sensitivity, specificity, positive predictive value, and negative predictive value for these measures, with “lack of transition to dementia” as the gold standard/target. “Lack of cognitive decline” (cognitively unimpaired to mild cognitive impairment [MCI]; cognitively unimpaired to dementia; or MCI to dementia) was a secondary target.Result94.7% of participants (613/647) did not transition to dementia and 84.2% (545/647) did not cognitively decline over 11.25‐year‐follow‐up. The combination of intact BSIT+BIMCT had high rates of lack of transition to dementia (98.3%, 355/361) and lack of cognitive decline (93.1%, 336/361). This combination yielded mixed sensitivity (0.579) and specificity (0.824) though had high positive predictive value (0.983) for identifying lack of transition to dementia. Intact amyloid PET alone exhibited comparable rates of lack of transition to dementia (99.0%, 418/423) and lack of cognitive decline (92.4%, 391/423). When evaluated conjointly, the combination of all three intact measures also had mixed sensitivity (0.421) and specificity (0.962) though higher positive predictive value (PPV = 0.996) for lack of transition to dementia. 99.6% (258/259) of participants with intact/normal status on all three did not transition to dementia and 96.5% (250/259) did not cognitively decline.ConclusionThis replicates prior reports that intact olfaction/global cognition have strong utility for identifying individuals unlikely to develop MCI/dementia. Intact/normal amyloid PET further enhances the positive predictive value. Clinically, identifying individuals at low risk of transition can shorten diagnostic workups, reduce need for early follow‐up visits, and screen patients in‐or‐out of clinical trials.
Mayo Normative Studies: regression‐based normative data for remote self‐administration of the Stricker Learning Span, Symbols Test and Mayo Test Drive Screening Battery Composite for ages 33‐100 and validation in MCI and dementia
Frank, Ryan D. , Fan, Winnie Z. , Christianson, Teresa J., Stricker, John L. , Lucas, John A. , Graff‐Radford, Jonathan, Petersen, Ronald C. , Stricker, Nikki H. , Boots, Elizabeth A. , Kremers, Walter K. , Machulda, Mary M. , Hassenstab, Jason , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.085612 Get It

AbstractBackgroundFew normative data for computerized measures administered in unsupervised remote environments are available. We aimed to determine what variables to include in normative models for remote self‐administered assessments, develop normative data for measures administered through Mayo Test Drive (MTD, a multi‐device remote cognitive assessment platform) and evaluate application of norms.Method1240 adults ages 33‐100 (96% White) from the Mayo Clinic Study of Aging and Mayo Alzheimer’s Disease Research Center met normative sample inclusion criteria that included a concordant Cognitively Unimpaired (CU) diagnosis (3 independent raters all diagnosed CU) and CDR = 0 (see Table 1 for sample characteristics). Raw test scores were converted to normalized scaled scores. We derived regression‐based normative data that adjusted for age, age2, sex and education (base model); alternative models are also provided (age+age2+sex; age+ age2). We evaluated whether additional model terms beyond the base model were needed using an a priori cut‐off of 1% variance improvement in adjusted R2 over and above the base model. We examined rates of low test performance defined as performance below ‐1 SD in independent validation samples (n = 167 concordant CU, n = 64 mild cognitive impairment (MCI), n = 14 dementia). Rates are considered significantly different than expected when 95% confidence intervals (CIs) do not include the expected 14.7% base rate frequency.ResultNo additional potential model terms met our a priori cut‐off for inclusion beyond the base model (see Table 2), including other quadratic and cubic terms or interactions, device type, response input type, potential session interference, and national area deprivation index (ADI available in subset; N = 776). Application of norms showed expected rates of low test performance among CU participants (95% CI includes expected base rate) and significantly greater than expected rates of low test performance for all variables in MCI (e.g., 62.5% for composite) and dementia (e.g., 71.4% for composite; see Table 3).ConclusionTypical normative models appear appropriate for remote self‐administered measures and are sensitive to cognitive impairment. Device type and response input did not explain enough variance to warrant inclusion in normative models but are important for individual level interpretation. Future work will improve representation of individuals from under‐represented groups.
Treatment Pattern and Outcome of Locally Advanced Rectal Cancer in Resource-Constrained Countries: Experience at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia
Hailu, Elias Amare , Tadesse, Biruk Legesse , Dibaba, Abdi Dandena , Zingeta, Girum Tessema , Kelemu, Hidagewoin Frew, Zewde, Yonas Alemayehu, Aytehgeza, Ruth Shimeles , Begna, Kebede H. , Woldetsadik, Edom Seife , Tadesse, Biruk Legesse , Dibaba, Abdi Dandena , Zingeta, Girum Tessema , Aytehgeza, Ruth Shimeles , Begna, Kebede , Hailu, Elias Amare

Mayo Clinic

JCO Global Oncology | January 2, 2025 | Volume: No volume available | Issue: 11 | Pages: No page available

10.1200/go.23.00407 | PMID 39746169 Get It

PURPOSE Management of locally advanced rectal cancer (LARC) includes neoadjuvant chemoradiotherapy (NACRT) followed by total mesorectal excision. Recently, total neoadjuvant treatment (TNT) has gained attention. In developing countries, patients with rectal cancer often present at advanced stages. This study assesses treatment patterns and outcomes in LARC at a largest referral center in Ethiopia. MATERIALS AND METHODS A cross-sectional study was conducted on 100 patients with LARC treated at Tikur Anbessa Specialized Hospital from January 2020 to September 2022. RESULTS The median age at diagnosis was 45.5 years (range, 20-86), with 51% male. Of the patients, 81% had no previous oncologic treatment and 75.3% was discussed in a multidisciplinary tumor board. Up-front surgery was planned for 44.4% of patients, whereas 22.2% and 8.6% were assigned to TNT and NACRT, respectively. Among 81 treatment-naïve patients, 79 were triaged for surgery, but only 47 (59.5%) underwent surgery, achieving an 89.9% R0 resection rate. Of 36 up-front planned surgeries, 35 proceeded as planned, whereas only 12 of 43 (28%) planned after neoadjuvant treatment underwent surgery. Neoadjuvant chemotherapy (NACT) was given to 37% of patients, with 16.7% (5 of 30) undergoing subsequent surgery. Radiotherapy was given to 24.2% of participants, with 56.25% undergoing surgery. Short-course radiotherapy (SCRT) was given to two patients. Only 14.8% completed all planned treatments, with radiation waiting time (median, 10 months) being the main impediment. CONCLUSION Timely administration of neoadjuvant treatment is not possible in most resource-limited settings. Because of better treatment completion, up-front surgery looks a more viable option than NACT in these situations. Extended waiting time for radiotherapy can be mitigated by opting for alternatives like SCRT in selected patients.
Risk of Acute Cholecystitis Based on Combination of Patient Age, Patient Sex, Leukocytosis, and Sonographic Murphy Sign
Patel, Anika G. , Chen, Lea , Young, Scott W. , Dahiya, Nirvikar , Zhang, Nan , Patel, Maitray D , Young, Scott W , Patel, Maitray D.

Mayo Clinic

Journal of Ultrasound in Medicine | January 2, 2025 | Volume: 44 | Issue: 5 | Pages: 807-816

10.1002/jum.16640 | PMID 39745905 Get It

ObjectivesTo combine sonographic Murphy sign (SMS) with clinical parameters to effectively stratify patients into risk groups for acute cholecystitis.MethodsConsecutive emergency department patients from April 1, 2019 to August 31, 2022 with possible acute cholecystitis were grouped using patient age, sex, and white blood cell count to determine the rate of acute cholecystitis found in subgroups. Three distinct clinical risk groups were established and then regrouped by prospective assessment of SMS into three non‐imaging risk groups. Differences in the rate of acute cholecystitis for clinical parameters, clinical risk groups, and non‐imaging risk groups were statistically analyzed.ResultsOf 1231 patients (mean [SD] age, 51.2 [19.5]; 476 [38.7%] male), 156 had acute cholecystitis (mean [SD] age, 62.0 [15.4]; 85 [54.5%] male). Rates differed based on sex (9.4% female vs 17.9% male, P < .001), age group (1.8% for patients <30 years, 9.0% for patients 30–59 years, 22.3% for patients ≥60 years; P < .001), and white blood cell count (23.1% elevated vs 6.6% not elevated; P < .001). The low, average, and high non‐imaging risk groups had acute cholecystitis rates of 1.8%, 14.0%, and 43.1%, respectively. Relative risk (95% CI) for the low non‐imaging group compared with others was 0.07 (0.04, 0.12; P < .001); relative risk for the high non‐imaging risk group compared with others was 7.05 (5.32, 9.43; P < .001).ConclusionsSonographic Murphy sign assessment combined with patient age, sex, and white blood cell count effectively stratifies acute care patients into distinct acute cholecystitis risk groups.
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults
Daw, Stephen , Cole, Peter D. , Garnier, Nathalie , Buffardi, Salvatore, Mascarin, Maurizio , Lissat, Andrej , Mauz‐Körholz, Christine , Krajewski, Jennifer , Akyol, Alev, Crowe, Russell, Drachtman, Richard A. , Kelly, Kara M. , Leblanc, Thierry , Harker‐Murray, Paul , Hoppe, Bradford S. , Hodgson, David , Beishuizen, Auke , Anderson, Bailey , Xu, Yan , Leblanc, Thierry

Mayo Clinic

JAMA Oncology | January 2, 2025 | Volume: 11 | Issue: 3 | Pages: 249

10.1001/jamaoncol.2024.5627 | PMID 39745739 Get It

ImportanceRetrieval strategies for children, adolescents, and young adults with relapsed classic Hodgkin lymphoma (cHL) aim to maintain efficacy while minimizing long-term toxic effects. Children, adolescents, and young adults with low-risk, relapsed cHL may benefit from replacing high-dose chemotherapy and autologous stem cell transplant with less intensive involved-site radiotherapy (ISRT).ObjectiveTo evaluate a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed cHL with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response and ISRT (30.0 to 30.6 Gy).Design, Setting, and ParticipantsCheckMate 744 (R1 cohort) was a phase 2, nonrandomized, single-arm study enrolling children, adolescents, and young adults aged 5 to 30 years with low-risk cHL between September 25, 2017, and December 16, 2020, across the US, Canada, and Europe. Data were analyzed from September 2017 to November 2022.ExposuresPatients received 4 cycles of nivolumab plus BV induction; patients with complete metabolic response (CMR) received an additional 2 cycles of nivolumab plus BV while patients with suboptimal response received 2 cycles of BV plus bendamustine intensification. Patients with CMR after induction or intensification received ISRT consolidation.Main Outcomes and MeasuresPrespecified coprimary end points were CMR rate (Lugano 2014 classification) any time before ISRT and 3-year event-free survival (EFS) rate, per blinded independent central review (BICR).ResultsOf 28 included patients treated in the low-risk cohort, 18 (64%) were female, and the median (range) age was 17 (6-27) years. At a median (range) follow-up of 31.9 (2.2-55.3) months, CMR per BICR any time before ISRT was 93% (26 of 28; 90% CI, 79.2-98.7; objective response rate [ORR], 100%), and 23 of 28 (82%) achieved CMR per BICR after 4 cycles of nivolumab plus BV (ORR, 96.4%). Kaplan-Meier estimates of EFS and progression-free survival rates at 3 years were 87% (3 of 18; 90% CI, 69.5-94.7) and 95% (1 of 18; 90% CI, 76.7-99.0), respectively. During induction, 22 patients (79%) had treatment-related adverse events, including 7 with grade 3 or 4 adverse events, 2 with anemia, 1 with neutropenia, and 6 with immune-mediated adverse events. Serious adverse events leading to discontinuation occurred in 2 patients.Conclusions and RelevanceThis nonrandomized clinical trial found that for children, adolescents, and young adults with low-risk, relapsed cHL, a transplant-free, risk-adapted, response-based approach with nivolumab plus BV and ISRT offered high CMR rates and high 3-year EFS rate, with a safety profile consistent with that of each agent used.Trial RegistrationClinicalTrials.gov Identifier: NCT02927769
Enhancing Robotic Arm Activity Recognition with Vision Transformers and Wavelet-Transformed Channel State Information
Zandi, Rojin , Behzad, Kian , Motamedi, Elaheh , Salehinejad, Hojjat , Siami, Milad

Mayo Clinic

2024 IEEE 35th International Symposium on Personal, Indoor and Mobile Radio Communications (PIMRC) | January 1, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/pimrc59610.2024.10817193 Get It